Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1S2FZ)

Drug Name

Cemdisiran Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Haemolytic uraemic syndrome	3A21.2	Phase 2	[1]
Paroxysmal nocturnal haemoglobinuria	3A21.0	Phase 2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C5 messenger RNA (C5 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALN-CC5	DMWYMJN	Haemolytic uraemic syndrome	3A21.2	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03303313) A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02352493) A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
4	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492.